ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Includes May issue of Business & Regulatory Report.

May 31, 2002

NCI Needs 100 SBIR Contracts By April 1 To Avoid Losing $5 Million; NIH Objects To DCT Comments

March 22, 1985

Emory Executive Objects to Report On Merit review

July 22, 1977

‘Approval to Apply’ For Proton Facility Upgrade Denied

February 24, 1989

Scientists, advocates voice objections to von Eschenbach’s conflicts, 2015.

November 23, 2005

Ten Cooperative Group Chairs Propose Eight “Guiding Principles” For Change

May 20, 2011